AVNS · As filed with the SEC
Avanos Medical cash flow statement, by quarter
The statement as Avanos Medical presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONDENSED CONSOLIDATED CASH FLOW STATEMENTS · USD
| USD | Q1 2026 3 months ended Mar 31, 2026 | Q4 2025† 3 months ended Dec 31, 2025 | Q3 2025† 3 months ended Sep 30, 2025 | Q2 2025† 3 months ended Jun 30, 2025 | Q1 2025 3 months ended Mar 31, 2025 | Q4 2024† 3 months ended Dec 31, 2024 | Q3 2024† 3 months ended Sep 30, 2024 | Q2 2024† 3 months ended Jun 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net income | 5,100,000 | (1,300,000)† | (1,400,000)† | (76,800,000)† | 6,600,000 | (397,300,000)† | 4,300,000† | 1,800,000† |
| Depreciation and amortization | 10,200,000 | 9,900,000† | 9,400,000† | 10,000,000† | 9,600,000 | 11,100,000† | 11,700,000† | 11,300,000† |
| Stock-based compensation expense | 3,700,000 | 1,200,000† | 3,500,000† | 4,100,000† | 3,800,000 | 3,800,000† | 2,600,000† | 3,800,000† |
| Goodwill impairment | — | — | 0† | — | — | — | 0† | — |
| Net loss on asset dispositions | 100,000 | — | 5,400,000† | 100,000† | 200,000 | — | 100,000† | 0† |
| Changes in operating assets and liabilities, net of acquisition: | ||||||||
| Accounts receivable | (300,000) | 8,100,000† | 700,000† | (3,000,000)† | 25,100,000 | 300,000† | (7,700,000)† | (7,400,000)† |
| Inventories | 6,100,000 | 2,800,000† | (500,000)† | (3,300,000)† | 1,200,000 | 44,900,000† | 1,900,000† | (3,100,000)† |
| Prepaid expenses and other assets | (2,400,000) | 3,000,000† | (3,800,000)† | 1,900,000† | 300,000 | 7,200,000† | 3,700,000† | 4,200,000† |
| Accounts payable | (2,100,000) | 1,100,000† | 1,100,000† | 4,800,000† | (6,400,000) | 300,000† | (1,200,000)† | (2,300,000)† |
| Accrued expenses | (33,700,000) | 9,500,000† | (400,000)† | (7,200,000)† | (14,800,000) | (7,700,000)† | 7,000,000† | 16,900,000† |
| Deferred income taxes and other | 1,000,000 | (9,700,000)† | 0† | (800,000)† | 100,000 | (42,200,000)† | 600,000† | 2,600,000† |
| Cash (Used in) Provided by Operating Activities | (12,300,000) | 28,200,000† | 14,000,000† | 6,800,000† | 25,700,000 | 57,900,000† | 23,000,000† | 27,800,000† |
| Investing Activities | ||||||||
| Capital expenditures | (4,300,000) | (6,900,000)† | (7,000,000)† | (11,000,000)† | (6,700,000) | (4,800,000)† | (3,000,000)† | (5,900,000)† |
| Proceeds from the sale of assets | — | 0† | — | — | — | 0† | — | — |
| Proceeds from the RH divestiture | — | 0† | 0† | 0† | 0 | (2,100,000)† | 0† | 0† |
| Acquisition of assets and investments in businesses | — | — | — | — | — | — | 0† | — |
| Investments in non-affiliates | — | (200,000)† | (200,000)† | (2,200,000)† | (2,400,000) | (2,800,000)† | (9,000,000)† | 0† |
| Investments in non-affiliates | (3,400,000) | — | — | — | — | — | — | — |
| Cash Used in Investing Activities | (7,700,000) | (6,800,000)† | (31,500,000)† | (13,200,000)† | (9,100,000) | (7,600,000)† | (12,000,000)† | (5,900,000)† |
| Financing Activities | ||||||||
| Secured debt repayments | (2,300,000) | (2,400,000)† | (2,300,000)† | (2,400,000)† | (2,300,000) | (2,300,000)† | (3,200,000)† | (1,500,000)† |
| Revolving credit facility proceeds | — | 0† | 0† | 0† | 0 | 0† | 0† | 0† |
| Revolving credit facility repayments | 0 | 0† | 0† | 0† | (25,000,000) | (25,000,000)† | (10,000,000)† | 0† |
| Purchases of treasury stock | (1,300,000) | (300,000)† | 0† | (800,000)† | (2,200,000) | (100,000)† | (100,000)† | (3,500,000)† |
| Proceeds from the exercise of stock options | 400,000 | 0† | 300,000† | 0† | 400,000 | 0† | 600,000† | 0† |
| Payment of contingent consideration liabilities | — | 0† | 0† | 0† | 0 | 0† | (3,300,000)† | 0† |
| Cash Used in Financing Activities | (3,200,000) | (2,700,000)† | (2,000,000)† | (3,200,000)† | (29,100,000) | (27,400,000)† | (16,000,000)† | (5,000,000)† |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | (1,000,000) | 600,000† | (300,000)† | 2,900,000† | 1,800,000 | (4,200,000)† | 1,800,000† | (500,000)† |
| Decrease in Cash and Cash Equivalents | (24,200,000) | 19,300,000† | (19,800,000)† | (6,700,000)† | (10,700,000) | 18,700,000† | (3,200,000)† | 16,400,000† |
| Cash and Cash Equivalents - Beginning of Period | 89,800,000 | 70,500,000 | 90,300,000 | 97,000,000 | 107,700,000 | 89,000,000 | 92,200,000 | 75,800,000 |
| Cash and Cash Equivalents - End of Period | 65,600,000 | 89,800,000 | 70,500,000 | 90,300,000 | 97,000,000 | 107,700,000 | 89,000,000 | 92,200,000 |
† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.